{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:05:06Z","timestamp":1790399106993,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671583"],"award-info":[{"award-number":["81671583"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971505"],"award-info":[{"award-number":["81971505"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771271"],"award-info":[{"award-number":["81771271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971506"],"award-info":[{"award-number":["81971506"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2018YFA0108304"],"award-info":[{"award-number":["2018YFA0108304"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Fujian Provincial Health Education Joint Research Project","award":["WKJ2016-2-20"],"award-info":[{"award-number":["WKJ2016-2-20"]}]},{"name":"key laboratory of functional and clinical translational medicine, Fujian province university","award":["JNYLC1813"],"award-info":[{"award-number":["JNYLC1813"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system characterized by severe white matter demyelination. Because of its complex pathogenesis, there is no definite cure for MS. Experimental autoimmune encephalomyelitis (EAE) is an ideal animal model for the study of MS. Arsenic trioxide (ATO) is an ancient Chinese medicine used for its therapeutic properties with several autoimmune diseases. It is also used to inhibit acute immune rejection due to its anti-inflammatory and immunosuppressive properties. However, it is unclear whether ATO has a therapeutic effect on EAE, and the underlying mechanisms have not yet been clearly elucidated. In this study, we attempted to assess whether ATO could be used to ameliorate EAE in mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      ATO (0.5\u2009mg\/kg\/day) was administered intraperitoneally to EAE mice 10 days post-immunization for 8 days. On day 22 post-immunization, the spinal cord, spleen, and blood were collected to analyze demyelination, inflammation, microglia activation, and the proportion of CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells. In vitro, for mechanistic studies, CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells were sorted from the spleen of na\u00efve C57BL\/6 mice and treated with ATO and then used for an apoptosis assay, JC-1 staining, imaging under a transmission electron microscope, and western blotting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ATO delayed the onset of EAE and alleviated the severity of EAE in mice. Treatment with ATO also attenuated demyelination, alleviated inflammation, reduced microglia activation, and decreased the expression levels of IL-2, IFN-\u03b3, IL-1\u03b2, IL-6, and TNF-\u03b1 in EAE mice. Moreover, the number and proportion of CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells in the spinal cord, spleen, and peripheral blood were reduced in ATO-treated EAE mice. Finally, ATO induced CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cell apoptosis via the mitochondrial pathway both in vitro and in vivo. Additionally, the administration of ATO had no adverse effect on the heart, liver, or kidney function, nor did it induce apoptosis in the spinal cord.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, our findings indicated that ATO plays a protective role in the initiation and progression of EAE and has the potential to be a novel drug in the treatment of MS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-020-01829-x","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T04:06:01Z","timestamp":1588737961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Arsenic trioxide ameliorates experimental autoimmune encephalomyelitis in C57BL\/6 mice by inducing CD4+ T cell apoptosis"],"prefix":"10.1186","volume":"17","author":[{"given":"Ke","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Jiao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ying","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Shu","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Quan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"1829_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMra052130","volume":"354","author":"EM Frohman","year":"2006","unstructured":"Frohman EM, Racke MK, Raine CS. Multiple sclerosis\u2014the plaque and its pathogenesis. N Engl J Med. 2006;354:942\u201355.","journal-title":"N Engl J Med."},{"key":"1829_CR2","doi-asserted-by":"crossref","unstructured":"Sperandeo K, Nogrady L, Moreo K, Prostko CR. Managed approaches to multiple sclerosis in special populations. J Manag Care Pharm. 2011;17:S1-19; quiz S20-1.","DOI":"10.18553\/jmcp.2011.17.s9-c.1"},{"key":"1829_CR3","doi-asserted-by":"publisher","first-page":"M174","DOI":"10.12968\/hmed.2011.72.Sup11.M174","volume":"72","author":"G Hassan-Smith","year":"2011","unstructured":"Hassan-Smith G, Douglas MR. Management and prognosis of multiple sclerosis. Br J Hosp Med (Lond). 2011;72:M174\u20136.","journal-title":"Br J Hosp Med (Lond)."},{"key":"1829_CR4","doi-asserted-by":"publisher","first-page":"i3518","DOI":"10.1136\/bmj.i3518","volume":"354","author":"DM Wingerchuk","year":"2016","unstructured":"Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518.","journal-title":"BMJ."},{"key":"1829_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.msard.2014.05.002","volume":"3","author":"D Baker","year":"2014","unstructured":"Baker D, Amor S. Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely. Mult Scler Relat Disord. 2014;3:555\u201364.","journal-title":"Mult Scler Relat Disord."},{"key":"1829_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2040-7378-1-5","volume":"1","author":"RA Linker","year":"2009","unstructured":"Linker RA, Lee DH. Models of autoimmune demyelination in the central nervous system: on the way to translational medicine. Exp Transl Stroke Med. 2009;1:5.","journal-title":"Exp Transl Stroke Med."},{"key":"1829_CR7","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.4049\/jimmunol.161.12.7015","volume":"161","author":"JJ Bright","year":"1998","unstructured":"Bright JJ, Du C, Coon M, Sriram S, Klaus SJ. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline. J Immunol. 1998;161:7015\u201322.","journal-title":"J Immunol."},{"key":"1829_CR8","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1101\/gad.14.14.1693","volume":"14","author":"LH Glimcher","year":"2000","unstructured":"Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev. 2000;14:1693\u2013711.","journal-title":"Genes Dev."},{"key":"1829_CR9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/jat.1649","volume":"31","author":"K Jomova","year":"2011","unstructured":"Jomova K, Jenisova Z, Feszterova M, Baros S, Liska J, Hudecova D, et al. Arsenic: toxicity, oxidative stress and human disease. J Appl Toxicol. 2011;31:95\u2013107.","journal-title":"J Appl Toxicol."},{"key":"1829_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.etap.2016.10.020","volume":"48","author":"A Sattar","year":"2016","unstructured":"Sattar A, Xie S, Hafeez MA, Wang X, Hussain HI, Iqbal Z, et al. Metabolism and toxicity of arsenicals in mammals. Environ Toxicol Pharmacol. 2016;48:214\u201324.","journal-title":"Environ Toxicol Pharmacol."},{"key":"1829_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1196\/annals.1454.049","volume":"1140","author":"EK Silbergeld","year":"2008","unstructured":"Silbergeld EK, Nachman K. The environmental and public health risks associated with arsenical use in animal feeds. Ann N Y Acad Sci. 2008;1140:346\u201357.","journal-title":"Ann N Y Acad Sci."},{"key":"1829_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0048-9697(98)00180-6","volume":"218","author":"EA Murphy","year":"1998","unstructured":"Murphy EA, Aucott M. An assessment of the amounts of arsenical pesticides used historically in a geographical area. Sci Total Environ. 1998;218:89\u2013101.","journal-title":"Sci Total Environ."},{"key":"1829_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00775-018-1537-9","volume":"23","author":"M Hoonjan","year":"2018","unstructured":"Hoonjan M, Jadhav V, Bhatt P. Arsenic trioxide: insights into its evolution to an anticancer agent. J Biol Inorg Chem. 2018;23:313\u201329.","journal-title":"J Biol Inorg Chem."},{"key":"1829_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ctrv.2007.05.001","volume":"33","author":"PJ Dilda","year":"2007","unstructured":"Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. Cancer Treat Rev. 2007;33:542\u201364.","journal-title":"Cancer Treat Rev."},{"key":"1829_CR15","first-page":"44","volume":"31","author":"A Perdrup","year":"1950","unstructured":"Perdrup A. Penicillin versus arsenical-bismuth treatment in early syphilis. Acta Derm Venereol Suppl (Stockh). 1950;31:44\u20138.","journal-title":"Acta Derm Venereol Suppl (Stockh)."},{"key":"1829_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2146\/ajhp080342","volume":"66","author":"L Leu","year":"2009","unstructured":"Leu L, Mohassel L. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Am J Health Syst Pharm. 2009;66:1913\u20138.","journal-title":"Am J Health Syst Pharm."},{"key":"1829_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1126\/science.1183424","volume":"328","author":"XW Zhang","year":"2010","unstructured":"Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 2010;328:240\u20133.","journal-title":"Science."},{"key":"1829_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/cmi.2010.26","volume":"7","author":"KH Chu","year":"2010","unstructured":"Chu KH, Lee CC, Hsin SC, Cai BC, Wang JH, Chiang BL. Arsenic trioxide alleviates airway hyperresponsiveness and eosinophilia in a murine model of asthma. Cell Mol Immunol. 2010;7:375\u201380.","journal-title":"Cell Mol Immunol."},{"key":"1829_CR19","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1182\/blood-2006-04-020610","volume":"108","author":"P Bobe","year":"2006","unstructured":"Bobe P, Bonardelle D, Benihoud K, Opolon P, Chelbi-Alix MK. Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL\/lpr mice. Blood. 2006;108:3967\u201375.","journal-title":"Blood."},{"key":"1829_CR20","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1111\/bjh.15982","volume":"186","author":"X Hu","year":"2019","unstructured":"Hu X, Li L, Yan S, Li Z. Arsenic trioxide suppresses acute graft-versus-host disease by activating the Nrf2\/HO-1 pathway in mice. Br J Haematol. 2019;186:e145\u2013e8.","journal-title":"Br J Haematol."},{"key":"1829_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.trim.2015.05.004","volume":"33","author":"C Li","year":"2015","unstructured":"Li C, Guan T, Gao C, Lin Y, Yan G, Zhu M, et al. Arsenic trioxide inhibits accelerated allograft rejection mediated by alloreactive CD8(+) memory T cells and prolongs allograft survival time. Transpl Immunol. 2015;33:30\u20136.","journal-title":"Transpl Immunol."},{"key":"1829_CR22","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1097\/TP.0000000000000735","volume":"99","author":"C Gao","year":"2015","unstructured":"Gao C, Jiang J, Ma P, Cheng P, Lian Y, Zhao B, et al. Arsenic trioxide induces T cell apoptosis and prolongs islet allograft survival in mice. Transplantation. 2015;99:1796\u2013806.","journal-title":"Transplantation."},{"key":"1829_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008720","volume":"5","author":"A Rynda","year":"2010","unstructured":"Rynda A, Maddaloni M, Ochoa-Reparaz J, Callis G, Pascual DW. IL-28 supplants requirement for T(reg) cells in protein sigma1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE). PLoS One. 2010;5:e8720.","journal-title":"PLoS One."},{"key":"1829_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1134\/S0006297918090110","volume":"83","author":"VS Gogoleva","year":"2018","unstructured":"Gogoleva VS, Atretkhany KN, Drutskaya MS, Mufazalov IA, Kruglov AA, Nedospasov SA. cytokines as mediators of neuroinflammation in experimental autoimmune encephalomyelitis. Biochemistry (Mosc). 2018;83:1089\u2013103.","journal-title":"Biochemistry (Mosc)."},{"key":"1829_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jns.2013.03.002","volume":"333","author":"A Rostami","year":"2013","unstructured":"Rostami A, Ciric B. Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci. 2013;333:76\u201387.","journal-title":"J Neurol Sci."},{"key":"1829_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00415-005-0965-y","volume":"253","author":"M Ruggieri","year":"2006","unstructured":"Ruggieri M, Avolio C, Scacco S, Pica C, Lia A, Zimatore GB, et al. Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients. J Neurol. 2006;253:231\u20136.","journal-title":"J Neurol."},{"key":"1829_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0165-5728(01)00422-2","volume":"120","author":"MK Sharief","year":"2001","unstructured":"Sharief MK, Semra YK, Seidi OA, Zoukos Y. Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol. 2001;120:199\u2013207.","journal-title":"J Neuroimmunol."},{"key":"1829_CR28","doi-asserted-by":"publisher","first-page":"4566","DOI":"10.1016\/j.vaccine.2010.04.074","volume":"28","author":"A Chhabra","year":"2010","unstructured":"Chhabra A. Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy. Vaccine. 2010;28:4566\u201372.","journal-title":"Vaccine."},{"key":"1829_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1756-9966-33-42","volume":"33","author":"S Kumar","year":"2014","unstructured":"Kumar S, Yedjou CG, Tchounwou PB. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. J Exp Clin Cancer Res. 2014;33:42.","journal-title":"J Exp Clin Cancer Res."},{"key":"1829_CR30","first-page":"1218","volume":"2016","author":"M Rothaug","year":"1863","unstructured":"Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 1863;2016:1218\u201327.","journal-title":"Biochim Biophys Acta."},{"key":"1829_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","volume":"74","author":"I Raphael","year":"2015","unstructured":"Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74:5\u201317.","journal-title":"Cytokine."},{"key":"1829_CR32","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.4049\/jimmunol.1700263","volume":"198","author":"CC Lin","year":"2017","unstructured":"Lin CC, Edelson BT. New insights into the role of IL-1beta in experimental autoimmune encephalomyelitis and multiple sclerosis. J Immunol. 2017;198:4553\u201360.","journal-title":"J Immunol."},{"key":"1829_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12974-016-0513-y","volume":"13","author":"A Valentin-Torres","year":"2016","unstructured":"Valentin-Torres A, Savarin C, Hinton DR, Phares TW, Bergmann CC, Stohlman SA. Sustained TNF production by central nervous system infiltrating macrophages promotes progressive autoimmune encephalomyelitis. J Neuroinflammation. 2016;13:46.","journal-title":"J Neuroinflammation."},{"key":"1829_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12011-017-1206-9","volume":"184","author":"H Hu","year":"2018","unstructured":"Hu H, Chen E, Li Y, Zhu X, Zhang T, Zhu X. Effects of arsenic trioxide on INF-gamma gene expression in MRL\/lpr mice and human lupus. Biol Trace Elem Res. 2018;184:391\u20137.","journal-title":"Biol Trace Elem Res."},{"key":"1829_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/acn3.67","volume":"1","author":"MK Mishra","year":"2014","unstructured":"Mishra MK, Wang J, Keough MB, Fan Y, Silva C, Sloka S, et al. Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Ann Clin Transl Neurol. 2014;1:409\u201322.","journal-title":"Ann Clin Transl Neurol."},{"key":"1829_CR36","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3389\/fncel.2018.00523","volume":"12","author":"A Wlodarczyk","year":"2019","unstructured":"Wlodarczyk A, Benmamar-Badel A, C\u00e9dile O, Jensen KN, Kramer I, Elsborg NB, et al. CSF1R stimulation promotes increased neuroprotection by CD11c+ microglia in EAE. Front Cell Neurosci. 2019;12:523.","journal-title":"Front Cell Neurosci."},{"key":"1829_CR37","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nature01325","volume":"420","author":"HL Weiner","year":"2002","unstructured":"Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature. 2002;420:879\u201384.","journal-title":"Nature."},{"key":"1829_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nm.2324","volume":"17","author":"I Nikic","year":"2011","unstructured":"Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2011;17:495\u20139.","journal-title":"Nat Med."},{"key":"1829_CR39","first-page":"19","volume":"178","author":"A Suzumura","year":"2006","unstructured":"Suzumura A. Neurotoxicity by microglia: mechanisms and potential therapeutic strategy. J Neuroimmunol. 2006;178:19\u201320.","journal-title":"J Neuroimmunol."},{"key":"1829_CR40","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1182\/blood-2011-05-354530","volume":"118","author":"WY Au","year":"2011","unstructured":"Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood. 2011;118:6535\u201343.","journal-title":"Blood."},{"key":"1829_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111\u201321.","journal-title":"N Engl J Med."},{"key":"1829_CR42","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","volume":"16","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:1295\u2013305.","journal-title":"Lancet Oncol."},{"key":"1829_CR43","doi-asserted-by":"crossref","unstructured":"Haybar H, Shahrabi S, Rezaeeyan H, Jodat H, Saki N. Strategies to inhibit arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia. J Cell Physiol. 2019.","DOI":"10.1002\/jcp.28292"},{"key":"1829_CR44","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.transproceed.2009.02.073","volume":"41","author":"S Yan","year":"2009","unstructured":"Yan S, Zhang QY, Zhou B, Xue L, Chen H, Wang Y, et al. Arsenic trioxide attenuated the rejection of major histocompatibility complex fully-mismatched cardiac allografts in mice. Transplant Proc. 2009;41:1855\u20138.","journal-title":"Transplant Proc."},{"key":"1829_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.trim.2010.07.003","volume":"24","author":"S Xu","year":"2010","unstructured":"Xu S, Chen J, Wang F, Kang X, Lan T, Wang F, et al. Arsenic trioxide combined with co-stimulatory molecule blockade prolongs survival of cardiac allografts in alloantigen-primed mice. Transpl Immunol. 2010;24:57\u201363.","journal-title":"Transpl Immunol."},{"key":"1829_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.trim.2011.08.002","volume":"25","author":"Y Lin","year":"2011","unstructured":"Lin Y, Dai H, Su J, Yan G, Xi Y, Ekberg H, et al. Arsenic trioxide is a novel agent for combination therapy to prolong heart allograft survival in allo-primed T cells transferred mice. Transpl Immunol. 2011;25:194\u2013201.","journal-title":"Transpl Immunol."},{"key":"1829_CR47","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fphar.2018.00487","volume":"9","author":"JY Zhang","year":"2018","unstructured":"Zhang JY, Wang M, Wang RY, Sun X, Du YY, Ye JX, et al. Salvianolic acid A ameliorates arsenic trioxide-induced cardiotoxicity through decreasing cardiac mitochondrial injury and promotes its anticancer activity. Front Pharmacol. 2018;9:487.","journal-title":"Front Pharmacol."},{"key":"1829_CR48","first-page":"3893","volume":"62","author":"WH Miller Jr","year":"2002","unstructured":"Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62:3893\u2013903.","journal-title":"Cancer Res."},{"key":"1829_CR49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1365-2141.2002.03421.x","volume":"117","author":"C Recher","year":"2002","unstructured":"Recher C, Chopin M, Raffoux E, Pierron G, Poupon J, Sigaux F, et al. In vitro and in vivo effectiveness of arsenic trioxide against murine T-cell prolymphocytic leukaemia. Br J Haematol. 2002;117:343\u201350.","journal-title":"Br J Haematol."},{"key":"1829_CR50","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.toxlet.2013.10.013","volume":"224","author":"TH Lu","year":"2014","unstructured":"Lu TH, Tseng TJ, Su CC, Tang FC, Yen CC, Liu YY, et al. Arsenic induces reactive oxygen species-caused neuronal cell apoptosis through JNK\/ERK-mediated mitochondria-dependent and GRP 78\/CHOP-regulated pathways. Toxicol Lett. 2014;224:130\u201340.","journal-title":"Toxicol Lett."},{"key":"1829_CR51","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jcb.20102","volume":"93","author":"SK Chow","year":"2004","unstructured":"Chow SK, Chan JY, Fung KP. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem. 2004;93:173\u201387.","journal-title":"J Cell Biochem."},{"key":"1829_CR52","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1081\/CNV-200029068","volume":"22","author":"X Li","year":"2004","unstructured":"Li X, Ding X, Adrian TE. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest. 2004;22:389\u2013400.","journal-title":"Cancer Invest."},{"key":"1829_CR53","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1525-1438.2005.00251.x","volume":"15","author":"B Kong","year":"2005","unstructured":"Kong B, Huang S, Wang W, Ma D, Qu X, Jiang J, et al. Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. Int J Gynecol Cancer. 2005;15:872\u20137.","journal-title":"Int J Gynecol Cancer."},{"key":"1829_CR54","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.3748\/wjg.v11.i36.5633","volume":"11","author":"LM Lin","year":"2005","unstructured":"Lin LM, Li BX, Xiao JB, Lin DH, Yang BF. Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro. World J Gastroenterol. 2005;11:5633\u20137.","journal-title":"World J Gastroenterol."},{"key":"1829_CR55","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/xen.12238","volume":"23","author":"ZX Jiao","year":"2016","unstructured":"Jiao ZX, Leng Y, Xia JJ, Wu HQ, Jin N, Fu JZ, et al. As2 O3 combined with leflunomide prolongs heart xenograft survival via suppressing the response of Th1, Th2, and B cells in a rat model. Xenotransplantation. 2016;23:237\u201348.","journal-title":"Xenotransplantation."},{"issue":"Suppl 2","key":"1829_CR56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/theoncologist.6-suppl_2-3","volume":"6","author":"S Waxman","year":"2001","unstructured":"Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist. 2001;6(Suppl 2):3\u201310.","journal-title":"Oncologist."},{"key":"1829_CR57","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1080\/1028415X.2016.1239399","volume":"21","author":"M Alizadeh-Ghodsi","year":"2018","unstructured":"Alizadeh-Ghodsi M, Zavvari A, Ebrahimi-Kalan A, Shiri-Shahsavar MR, Yousefi B. The hypothetical roles of arsenic in multiple sclerosis by induction of inflammation and aggregation of tau protein: A commentary. Nutr Neurosci. 2018;21:92\u20136.","journal-title":"Nutr Neurosci."},{"key":"1829_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.msard.2017.11.010","volume":"19","author":"KB Juybari","year":"2018","unstructured":"Juybari KB, Ebrahimi G, Momeni Moghaddam MA, Asadikaram G, Torkzadeh-Mahani M, Akbari M, et al. Evaluation of serum arsenic and its effects on antioxidant alterations in relapsing-remitting multiple sclerosis patients. Mult Scler Relat Disord. 2018;19:79\u201384.","journal-title":"Mult Scler Relat Disord."},{"key":"1829_CR59","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s10072-017-2934-5","volume":"38","author":"M Aliomrani","year":"2017","unstructured":"Aliomrani M, Sahraian MA, Shirkhanloo H, Sharifzadeh M, Khoshayand MR, Ghahremani MH. Correlation between heavy metal exposure and GSTM1 polymorphism in Iranian multiple sclerosis patients. Neurol Sci. 2017;38:1271\u20138.","journal-title":"Neurol Sci."},{"key":"1829_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065911","volume":"8","author":"CP Tsai","year":"2013","unstructured":"Tsai CP, Lee CT. Multiple sclerosis incidence associated with the soil lead and arsenic concentrations in Taiwan. PLoS One. 2013;8:e65911.","journal-title":"PLoS One."},{"key":"1829_CR61","doi-asserted-by":"crossref","unstructured":"Robertson DA, Low-Beer TS. Long term consequences of arsenical treatment for multiple sclerosis. Br Med J (Clin Res Ed). 1983;286:605-6.","DOI":"10.1136\/bmj.286.6365.605-a"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-01829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-020-01829-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-01829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T14:56:52Z","timestamp":1696085812000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-020-01829-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1829"],"URL":"https:\/\/doi.org\/10.1186\/s12974-020-01829-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.21122\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.21122\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.21122\/v3","asserted-by":"object"}]},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"12 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animals and experiments in this study were approved by the Animal Ethics Committee of Xiamen University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}